Lysogene: Lysogene: Hearing Scheduled on May 23, 2023 on the Possible Opening of Judicial Liquidation Proceedings

Regulatory News: Lysogene (FR0013233475 LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that on May 23, 2023, the Commercial Co...